CIK 0001478320 · Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- operating
- EIN
- 270907024
- Phone
- 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,491,115
- in 20 filings, $14.5M under 10b5-1 plans
Net −$33,491,115. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-04 | OWEN KATEY EINTERZ Director | Grant or award | +15,625 | 88,254 | ||
| 2026-03-04 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Grant or award | +59,375 | 406,613 | ||
| 2026-03-04 | BOBULSKY SUSAN Chief Commercial Officer, MRD | Grant or award | +62,500 | 469,113 | ||
| 2026-03-04 | BENZENO SHARON Chief Commercial Ofc Imm Med | Grant or award | +39,063 | 335,854 | ||
| 2026-03-04 | ROBINS HARLAN S Chief Scientific Officer | Grant or award | +127,813 | 1,283,104 | ||
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Grant or award | +81,250 | 656,485 | ||
| 2026-03-04 | PISKEL KYLE Chief Financial Officer | Grant or award | +61,875 | 278,512 | ||
| 2026-03-04 | LO FRANCIS Chief People Officer | Grant or award | +44,063 | 360,041 | ||
| 2026-03-04 | ROBINS CHAD M CEO and Chairman | Grant or award | +127,813 | 2,062,060 | ||
| 2026-03-04 | HERSHBERG ROBERT Director | Grant or award | +15,625 | 62,347 | ||
| 2026-03-04 | NEUPERT PETER M Director | Grant or award | +15,625 | 240,315 | ||
| 2026-03-04 | GRIFFIN MICHELLE RENEE Director | Grant or award | +15,625 | 31,019 | ||
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 | +14,722 | $6.55 | $96K | 598,633 |
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 | +11,881 | $12.14 | $144K | 610,514 |
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 | −30,941 | $16.60 | $514K | 579,573 |
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Option exercise · Stock Option (right to buy) 10b5-1 | −14,722 | 165,881 | ||
| 2026-03-04 | RUBINSTEIN JULIE President and COO | Option exercise · Stock Option (right to buy) 10b5-1 | −11,881 | 439,582 | ||
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 | +14,722 | $6.55 | $96K | 602,971 |
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Option exercise 10b5-1 | +11,881 | $12.14 | $144K | 614,852 |
| 2026-03-03 | RUBINSTEIN JULIE President and COO | Sale 10b5-1 | −24,423 | $15.49 | $378K | 590,429 |
Page 20 of 120 · 2,386 trades